Navigation Links
BioTrends Announces a New Syndicated Report Series, LaunchTrends(TM): Feraheme
Date:7/1/2009

EXTON, Pa., July 1 /PRNewswire/ -- In conjunction with yesterday's FDA approval of AMAG Pharmaceuticals' Feraheme (ferumoxytol), BioTrends Research Group, Inc. is pleased to announce LaunchTrends(TM): Feraheme, a syndicated report series that will track the trial, adoption and usage of Feraheme. Feraheme is a new IV Iron product approved to treat iron deficiency anemia in patients with Chronic Kidney Disease, both on and not on dialysis. Surveys will be fielded at one month, three months, and six months post launch. Each report consists of findings from a quantitative survey with 50 Nephrologists and qualitative interviews with a subset of the survey respondents.

BioTrends has been following Feraheme in its TreatmentTrends(R): US Nephrology reports since the end of 2006. According to the most recent TreatmentTrends(R) survey, interest in the product is high, particularly in the CKD-ND setting, although Nephrologists predict uptake across all patient types.

LaunchTrends(TM) measure launch effectiveness of new products from FDA approval through six months post launch. The first wave of the LaunchTrends(TM): Feraheme report series will be fielded in mid-August, measuring uptake at one month. Topline findings will be available shortly thereafter and the full report will follow in mid-September.

About BioTrends Research Group, Inc.

BioTrends Research Group, Inc. (www.bio-trends.com) provides syndicated and custom market research to pharmaceutical manufacturers competing in clinically evolving, specialty pharmaceutical markets. To purchase this report or to learn more about BioTrends' syndicated publications, please contact us at (610) 363-3872 or visit us at www.bio-trends.com.

All company, brand, or product names contained in this document may be trademarks of their respective holders.


'/>"/>
SOURCE BioTrends Research Group, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Product Shifts are Occurring in the Renal Anemia and Bone and Mineral Metabolism Markets According to the Most Recent TreatmentTrends(R): US Nephrology Report from BioTrends Research Group
2. New Report by BioTrends Research Group to Highlight the Launch of SIMPONI(R) (golimumab)
3. BioTrends Prepares to Field ChartTrends(TM) Reports to Cover the Use of Biologic Agents in Psoriasis and Rheumatoid Arthritis
4. New Study by BioTrends Highlights Practice Management Shifts Among Canadian Nephrologists
5. New York Citys World Product Centre Announces Initial Charter Partners
6. Ingenious Med Announces a New Coding & Compliance Tool, MasterCoder
7. Nielsen Announces First-Ever CLIO Healthcare Awards Now Accepting Entries
8. Industry Leader Announces Next Generation of Patient Flow Automation
9. HealthMEDX Announces Vision Solution
10. eDiets.com(R) Announces Meal Delivery Marketing Partnership With Golds Gym Franchise Network
11. Aftercad Announces Signup for the 3D Workspace Beta
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/27/2016)... ... June 27, 2016 , ... "FCPX editors can now ... of Final Cut Pro X," said Christina Austin - CEO of Pixel Film Studios. ... Final Cut Pro X users can now reveal the media of their split ...
(Date:6/26/2016)... ... ... Quality metrics are proliferating in cancer care, and are derived from many of ... beholder, according to experts who offered insights and commentary in the current issue of ... full issue, click here . , For the American Society of Clinical Oncology ...
(Date:6/26/2016)... Birmingham, Lake Orion, Clarkston, Michigan (PRWEB) , ... ... ... their direction with respect to fertility once they have been diagnosed with endometriosis. ... for tolerable intercourse but they also require a comprehensive approach that can help ...
(Date:6/25/2016)... ... June 25, 2016 , ... First Choice Emergency Room , ... Sesan Ogunleye, as the Medical Director of its new Mesquite-Samuell Farm facility. , ... our new Mesquite location,” said Dr. James M. Muzzarelli, Executive Medical Director of First ...
(Date:6/24/2016)... Angeles, CA (PRWEB) , ... June 24, 2016 , ... ... surgery procedures that most people are unfamiliar with. The article goes on to state ... procedures, but also many of these less common operations such as calf and cheek ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... , June 24, 2016  Global Blood ... biopharmaceutical company developing novel therapeutics for the treatment ... today announced the closing of its previously announced ... stock, at the public offering price of $18.75 ... offering were offered by GBT. GBT estimates net ...
(Date:6/24/2016)... June 24, 2016 The Academy of Managed ... recommendations that would allow biopharmaceutical companies to more ... that make formulary and coverage decisions, a move that ... new medicines. The recommendations address restrictions in ... on the drug label, a prohibition that hinders decision ...
(Date:6/24/2016)... , June 24, 2016 According ... by Type (Standard Pen Needles, Safety Pen Needles), Needle ... GLP-1, Growth Hormone), Mode of Purchase (Retail, Non-Retail) - ... This report studies the market for the forecast period ... reach USD 2.81 Billion by 2021 from USD 1.65 ...
Breaking Medicine Technology: